ORTEXORTEX News
Tracking FITB? Get live short interest, options flow, and signals on ORTEX.Sign up free →
FI
ConfluenceFITB

Evercore upgrade fires starter gun on FITB post-earnings re-rating

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 21 Oct 2026, 14:32

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Evercore ISI lifted FITB to Outperform this morning, raising its price target to $60 from $57. The stock is at $52.41, up 3.8% on Tuesday and 4.4% over the past week, outpacing the 2.5% median for its closest regional bank peers.

Evercore reverses course after Q3 beat

The upgrade is a reversal. Evercore's John Pancari had cut his target to $57 from $61 on October 1, keeping the stock at In-Line. Q3 earnings landed on October 19 with a 4.1% single-day gain. Pancari moved to Outperform the following morning.

The broader analyst picture has firmed around the same price point. RBC Capital maintained Outperform on October 20, though it trimmed its target to $60 from $62. TD Cowen reinstated Buy at $60 on October 8. UBS and JP Morgan have held Buy and Overweight ratings, respectively, with targets of $63 and $58. The consensus is Buy, with 14 buys against 4 holds. The mean price target across the group is $61.44, implying roughly 17% from current levels.

The bull case centres on the Comerica acquisition: a 2Q26 core return on average tangible common equity of 18.0%, net interest income up 14% sequentially to $2.22 billion, and management guiding for a return to buybacks. Bears point to rising nonaccrual loan inflows, integration costs including about $210 million of CDI amortization in 2026, and rate sensitivity.

Options market already made the call

Options traders were ahead of the analyst community. The put/call ratio hit 0.61 on October 20, the lowest in three years and 3.0 standard deviations below the 20-day mean of 0.66. That reading arrived before Evercore's note was published. Call positioning at this extreme, sustained over two consecutive sessions, was the options market pricing in a positive catalyst rather than hedging against one.

The 52-week range on the PCR runs from 0.47 to 1.20. At 0.61, the ratio is near the bullish end without yet touching the floor.

Borrow market: loose but stirring

The lending market remains very comfortable. Availability sits at 1,615%, meaning there are roughly 16 shares available to borrow for every one currently lent out. That is well above the 52-week tightest reading of 227%.

Cost to borrow has risen 32% over the past week to 0.49%, the pulse that triggered the third convergence signal. The absolute level is still low. What matters is the direction: CTB drifted as low as 0.31% on October 12 and has moved steadily higher since. Short interest itself is 4.5% of the free float, down 3% on the month from a spike that peaked at 38.5 million shares on September 30.

The FDIC call report data, covering Fifth Third's insured bank charters as of Q2, shows net loans and leases up 46% on Q2 last year and total deposits up 43% over the same period. That dataset has not been tested as a lead for the company's reported figures, so it is background context rather than a read-through to the next print.

Watch the October 21 close: the convergence of the Evercore upgrade, a three-year PCR low, and rising CTB in a loose borrow market all printed within a 32-hour window. The next scheduled earnings date is January 19, 2027.

Stocks in this article

See the live data behind this article on ORTEX.

Open FITB on ORTEX →

How this article was generated

Generated
21 Oct 2026, 14:36
Data as of
21 Oct 2026, 14:32
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.